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Abstract 
 2 
Context: Estrogens impact the incidence and progression of colorectal cancer (CRC) 
although precise molecular mechanisms remain ill-defined.  
Objective: Pre-receptor estrogen metabolism through steroid sulphatase (STS) and 17-
hydroxysteroid dehydrogenase activity and subsequent non-genomic estrogen signaling in 
human CRC tissue, in the TCGA COAD dataset, and in in vitro and in vivo CRC models was 
investigated. The study aimed to define and therapeutically target pathways through which 
estrogens alter CRC proliferation and progression.  
Design, Setting, Patients, and Interventions: Human CRC samples with normal tissue 
matched-controls were collected from post-menopausal female and age-matched male 
patients. Estrogen metabolism enzymes and non-genomic downstream signaling pathways 
were determined. CRC cell lines were transfected with STS and cultured for in vitro and in 
vivo analysis. Estrogen metabolism was determined through a novel uHPLC-MS/MS method.  
Primary Outcome Measure: The proliferative effects of estrogen metabolism were 
evaluated using BRdU assays and in CRC mouse xenograft studies. 
Results:  Human CRC exhibits dysregulated estrogen metabolism favoring estradiol 
synthesis. The activity of steroid sulfatase (STS), the fundamental enzyme that activates 
conjugated estrogens, is significantly (p<0.001) elevated in human CRC compared to 
matched controls. STS over-expression accelerates CRC proliferation in in vitro and in vivo 
models, with STS inhibition an effective treatment. Uniquely we define a G-protein coupled 
estrogen receptor (GPER) pro-proliferative pathway potentially through connective tissue 
growth factor (CTGF) in CRC. 
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Conclusion: Human CRC favors estradiol synthesis to augment proliferation via GPER-
stimulation. Further research is required on whether estrogen replacement therapy should be 
used with caution on patients at high-risk of developing CRC. 
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Introduction 
Controversy surrounds the role estrogens play in CRC (1). Observational studies from the 
Women’s Health Initiative (WHI) suggest pre-menopausal women have a 20% reduction in 
CRC compared to age-matched men (2). These gender differences plateau as women become 
post-menopausal. However, women on exogenous hormone-replacement therapy (HRT = 
conjugated estrogen (estrone sulfate (E1S)) plus medroxyprogesterone), maintain protection 
against CRC (3), and elevated endogenous plasma estrogen concentrations also protect 
against CRC incidence (4). Conversely, other studies suggest greater endogenous plasma 
estrone (E1) concentrations in post-menopausal women increase CRC risk (5); similarly, 
women with estrogen-dependent breast cancer have a higher risk of developing CRC (6). 
Importantly, women taking HRT at the time of CRC diagnoses are more likely to present with 
advanced-stage disease (7), suggesting either the symptoms associated with HRT use leads to 
delayed clinical diagnosis, or that HRT increases CRC development and proliferative rates.  
 
As HRT, and thus estrogens, may influence CRC proliferation, the local colonic tissue 
activation of estrogens via steroid sulfatase (STS) and 17-hydroxysteroid dehydrogenases 
(HSD17B) must be important (8). The expression of STS, the fundamental enzyme 
desulfating circulating estrogens to their active forms (Figure 1A), is prognostic for CRC 
survival (9), and mRNA expression of HSD172, which catalyzes estradiol (E2) to E1, is 
down-regulated in human CRC tissue (10) suggesting estrogen metabolism as important in 
CRC progression. However, little is known about HSD171, HSD177, and HSD1712 
expression, all of which activate E1 to E2 (11,12).  
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Questions also remain regarding how estrogens act in CRC.  ER has either low (13) or no 
(14) expression in both normal colon and CRC, although splice variants do exist (15). 
Furthermore, loss of the pro-apoptotic ER, which implies subsequent dominance of other 
ERs, defines CRC progression (16).   Indeed, a recent meta-analysis has confirmed the loss of 
ER expression as CRC develops (17). However, no human CRC studies have examined the 
G-protein coupled estrogen receptor (GPER), an endoplasmic reticulum membrane-bound 
receptor with high E2-binding affinity (18) with known pro-proliferative actions in breast (19) 
and endometrial cancer (20). 
 
Here we aimed to determine how estrogen metabolism and action impacts CRC. By 
examining key estrogen metabolizing enzymes in matched normal and cancerous human 
colorectal tissue, and then translating findings to in vitro and in vivo systems, we demonstrate 
for the first time that CRC exhibits dysregulated estrogen metabolism with STS activity and 
estrogen reductase pathways elevated in CRC. We go on to show greater STS activity 
increases estrogen-stimulated CRC proliferation in vitro and in vivo through GPER-activation 
via increased expression of connective tissue growth factor (CTGF), a known modulator of 
GPER action (21). Finally, we demonstrate that GPER expression is elevated in human CRC 
tissue, with this significantly correlating to increased CTGF expression. Thus, both STS and 
GPER inhibition may represent novel therapeutic targets for patients with CRC.  
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Results 
Estrogenic enzymes favor E2 metabolism in human CRC.  
Immunohistochemical studies show STS expression is increased in human CRC (9). 
However, as STS expression does not correlate with enzyme activity, and no data exists on 
STS activity in human colon, we determined STS activity in human CRC and 
histopathologically unchanged colonic mucosa located at least 10-20 cm away from 
cancerous lesions (see patient characteristics for 64 participants: Supplementary Table 1). 
Post-menopausal female and aged-matched male CRC STS activity was significantly 
increased in CRC tissue compared to matched tissue (percentage change (95% CI) 24.6 (10.3, 
38.8); p=0.001) (Table 1, Figure 1B). Although not formally tested, plotting the data suggests 
a more pronounced effect in females (Figure 1B). Increased STS activity does not correlate 
with increasing STS mRNA expression (STS dCT) in either normal or cancerous tissues 
(Figure 1C) (calculated correlation coefficient (p-value) g 0.27 (0.07) and 0.04 (0.77) for 
normal and cancerous samples, respectively). Indeed, RNASeq data (RNASeq V2) analyzed 
from The Cancer Genome Atlas (TCGA) colon adenocarcinoma (COAD) dataset showed no 
significant change in STS expression from normal to cancerous tissue (Supplementary Figure 
1). As STS activity is altered by various post-translational modifications (22) this suggests 
determining only STS expression does not represent in situ colon activity. Furthermore, STS 
activity does not correlate to Duke’s or T-staging (Table 1), indicating increased STS activity 
is most likely an early event in tumor formation.  
 
As STS desulfates circulating and peripheral E1S to E1, we next determined the expression of 
enzymes that oxidize E2 to E1 (HSD17B2) and reduce E1 to E2 (HSD171, HSD177, and 
HSD1712) in the same human CRC samples. HSD17B2 mRNA significantly (p<0.01) 
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decreased in CRC tissue compared to matched controls (Figure 1D, Supplementary Table 2, 
Supplementary Table 3 for raw dCT values). HSD171 mRNA was not detectable (data not 
shown). HSD177 and HSD1712 mRNA were significantly increased in female and male 
CRC tissue compared to matched controls (Supplementary Table 2, Supplementary Table 3 
for raw dCT values, and Figure 1E, 1F). This data was supported by further analysis of the 
TCGA COAD data, which demonstrated a significant decrease in mRNA expression of 
HSD17B2, and increased expression of HSD17B7 and HSD17B12, in colon cancer 
(Supplementary Figure 1). Immunoblotting (Figure 1G) and subsequent densitometry 
analysis (Figure 1H) of normal and cancerous tissue confirmed lack of HSD171 and 
increased HSD17B12 expression. HSD177 protein expression showed a trend towards 
increased expression in CRC. In contrast to mRNA data (Figure 1F), HSD172 protein was 
not decreased in CRC compared to controls (Figure 1H). HSD174, which oxidizes E1 to E2, 
expression was not determined as previous studies have shown this as significantly down-
regulated in human CRC (23). Taken together our data suggests CRC up-regulates pathways 
favoring E1S hydrolysis and subsequent E2 synthesis. 
 
Estrogen metabolizing enzyme expression defines CRC estrogenic proliferative 
response. 
As human CRC exhibited dysregulated estrogen metabolism we hypothesized CRC cell lines 
expressing E2 synthesis pathways may be more responsive to estrogen signaling. Thus, we 
determined expression patterns of key estrogen metabolizing enzymes in selected CRC cells. 
Compared to human CRC tissue, HCT116 and HT-29 cells exhibited similar HSD17 mRNA 
(data not shown) and protein (Figure 2A) expression (i.e. lack of HSD171, presence of 
HSD177 and HSD1712, limited HSD172 expression). In contrast, Caco2 cells have low 
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HSD177 and HSD1712, and higher HSD172 expression. Colo205 cells had low or no 
HSD17Bs mRNA (not shown) and protein expression and thus these cells were not used in 
further testing. When incubated for 72h with E1 (Figure 2B, raw absorbance data 
Supplementary Figure 2A) or E2 (Figure 2C, raw absorbance data Supplementary Figure 2B) 
in charcoal-stripped FBS (sFBS) media, HCT116 and HT-29 cells had increasing dose-
dependent proliferative rates compared to sFBS media controls. Caco2 cells failed to respond 
to E1 or E2 stimulation.  
 
Using LC-MS/MS we next examined how CRC cells metabolized estrogens over 24h. 
HCT116 cells did not significantly metabolize E2 to other oestrogen metabolites, HT-29 cells 
metabolized E2 to unknown metabolites, and Caco2 cells rapidly oxidized E2 to E1 (Figure 
2D and 2E) indicative of its high HSD17B2 reductase expression. This suggests oxidation of 
E2 via HSD172, expressed in Caco2 but not HCT116 and HT-29 cells, impacts local E2 
availability and consequently the ability of Caco2 cells proliferation to E2.  This further 
implies that peripheral estrogen metabolism in CRC may define the tumors responsiveness to 
estrogen action.  
 
STS over-expression augments E1S- and E2S-stimulated proliferation in CRC.   
As STS activity was significantly increased in human CRC samples (Fig. 1B), we examined 
how over-expression of STS affects CRC proliferation. Firstly, the STS activity of CRC cells 
was determined (Supplementary Figure 3A). Caco2 cells had the highest STS activity 
(165.4±4.7pmol/mg/h) with HCT116 cells exhibiting very low activity (1.65±0.1pmol/mg/h). 
Thus, we selected HCT116 cells to stably transduce with STS (HCT116[sts]) or vector only 
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(HCT116[vo]). Stable over-expression increased enzyme activity to 200.42±5.91pmol/mg/h 
compared to vector only expressing controls at 10.58±1.37pmol/mg/h (Supplementary Figure 
3B). 
In full media, HCT116[sts] proliferation significantly increased compared to HCT116[vo] 
cells (Figure 3A), with this augmented growth blocked by the non-cytotoxic, specific STS 
inhibitor STX64. Incubation of these same cells in sFBS media supplemented with E1, E2, or 
E1S (at 100nM) for 72h, a significant (p<0.001) growth difference was observed between 
HCT116[sts] and HCT116[vo] cells treated with E1S only (Supplementary Figure 3C). This 
demonstrates greater STS desulfation of E1S, leading to increased E1 liberation driving 
proliferation. When these cells were grown for 72h in sFBS supplemented with E2S (100nM), 
all proliferated in response to E2S, with the greatest increase seen in HCT116[sts] cells 
compared to sFBS controls (Figure 3B). STX64 blocked this increased growth suggesting 
estrogen desulfation as an important regulator in CRC proliferation.  
 
STS over-expression increases CRC xenograft growth.  
As HCT116[sts] cells exhibited increased proliferation in vitro, we next examined whether 
this effect was evident in an intact, female mouse CRC xenograft model. HCT116[sts] or 
HCT116[vo] cells (1 x 10
6
) were subcutaneous implanted into the flanks of female MF-1 
nude mice. Intact adult female mice were chosen as they have circulating E1S and E2S 
available for hydrolysis. Over 21 days, HCT116[sts] xenograft growth was significantly 
(p<0.01) greater compared to HCT116[vo] controls (Figure 3C), leading to a greater tumor 
burden by day 21 post implantation (Figure 3D and Figure 3E). Dosing of STX64 (20mg/kg, 
p.o., thrice weekly) initially completely stagnated (days 3–18) HCT116[sts] growth (Figure 
3C), although tumors were proliferating by day 24. Despite tumor STS activity being almost 
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completely ablated by STX64 treatment (Figure 3F), HCT116[vo] xenograft growth was not 
affected by STS inhibition. This suggests once STS is over-expressed, CRC may rely more 
heavily on estrogen desulfation as pro-proliferative. 
 
Estrogens increase proliferation through GPER signaling in CRC.  
As controversy surrounds how estrogens elicit their effects in CRC (24), we investigated 
whether GPER was expressed in human CRC and if GPER-stimulation augmented CRC 
proliferation. In contrast to HCT116 and HT-29 cells, Caco2 and Colo205 cells express 
ERNone of the CRC cell lines tested expressed ER, but all expressed GPER (Figure 4A). 
Others have shown (21) in breast cancer that GPER stimulation with E2 can increase 
proliferation and increase the expression of various downstream regulators of survival and 
migration (Figure 4B). Thus, we next examined whether the specific GPER agonist G1 (72h 
treatment) stimulated HCT116, HT-29 and Caco2 cell proliferation, as measured by BRdU 
incorporation, compared to sFBS controls (Figure 4C). G1 induced a dose-dependent 
stimulation in proliferation, with this effect more pronounced in HCT116 and HT-29. These 
results mimicked proliferative effects by E1 and E2 (see Figure 2B and Figure 2C). 
Intriguingly, Caco2 cells modestly responded to G1 treatment in contrast to their lack of 
increased proliferation in response to E2 (Figure 2B) supporting the notion that rapid E2 
oxidization in Caco2 limits estrogenic effects. However, when GPER is stimulated by G1, 
Caco2 cells can increase proliferation through this pathway. In HCT116 and HT-29 cells, the 
GPER antagonist G15 (1M) blocked both E2- and G1-stimulated proliferation over 72h 
compared to controls (Supplementary Figure 4A).  
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To further delineate GPER action in CRC, we also determined how E2 and G1 affected down-
stream molecular regulators of GPER action (21). Figure 4B illustrates the key genes that we 
examined in CRC cells, namely FOS, EGR1, ATF3, CTGF, DUSP1, and TNF. All these 
genes are upregulated in response to GPER stimulation in breast cancer cell lines (21). In HT-
29 cells EGR1 (Supplementary Figure 5A), ATF3 (Supplementary Figure 5B), DUSP1 
(Supplementary Figure 5C), and CTGF (Supplementary Figure 4D) but not FOS 
(Supplementary Figure 4E) and TNF(Supplementary Figure 4F), were significantly 
elevated in response to E2 (100nM for 24h) and G1 (100nM for 24h) compared to sFBS 
treated cells. In HCT116 cells, EGR1, ATF3 and CTGF were significantly elevated in 
response to treatment. As CTGF gave the largest response to E2 and G1 stimulation, we 
further examined its protein expression in response to treatment. In HCT116 and HT-29 cells, 
E2 (100nM) and G1 (100nM) increased CTGF protein expression after 24h as measured by 
immunoblotting (Figure 4D).  
 
To confirm the importance of GPER or CTGF in mediating the pro-proliferative effects of E2, 
we next did transient knockdown of these two proteins using siRNA and determined their 
response to E2 treatment. In HCT-116 cells, siRNA of GPER and CTGF provided protein 
knockdown for 96h, the length of time required for subsequent proliferation studies (Figure 
4E). Knockdown of GPER and CTGF significantly (p<0.001 and p<0.05, respectively) 
inhibited the proliferation driven by E2 and G1 in HCT-116 (Figure 4F). Intriguingly, when 
we again moved into an in vivo model of CRC, the use of the GPER antagonist G15 (at 
50g/kg i.p. thrice weekly) also significantly (p<0.01) inhibited HCT116[sts] xenograft 
growth implanted into female nude mice (Figure 4G). Indeed, interrogation of the TCGA 
COAD data-set indicated that although all estrogen receptors (ER, ER, and GPER) were 
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significantly (p<0.0001) down-regulated in CRC compared to normal controls 
(Supplementary Figure 6A), GPER still has the highest expression in CRC. Further analysis 
of the TCGA dataset demonstrated that patients with CRC tumors expressing high GPER had 
significantly (p=0.0431) poorer outcomes compared to low to mid expression levels (Figure 
4H). Indeed, CRC with high ER also had significantly (p=0.0265) worse outcomes 
(Supplementary Figure 6C), suggesting the importance of these pro-proliferative pathways in 
CRC. High ER expression did not affect CRC patient outcomes (Supplementary Figure 6D). 
With regards to CTGF expression, analysis of the TCGA COAD dataset showed increased 
expression in CRC compared to normal colon (Supplementary Figure 6B). CRC with high 
mRNA expression of CTGF resulted in a significantly (p=0.0272) poorer outcome 
(Supplementary Figure 6E). 
 
However, as mRNA and protein expression correlation is notoriously poor, hovering around 
40% explanatory power across many studies (25) and GPER protein expression was present 
in CRC cell lines (Figure 4A), we determined GPER protein expression in our human CRC 
samples and demonstrated an almost significant (p=0.054) increase in expression in CRC 
(Figure 5A, Figure 5B, and Supplementary Figure 7 shows all original immunoblots). CTGF 
mRNA (Supplementary Figure 6B) and protein was significantly (p<0.001) increased in CRC 
as determined by relative densitometry (Figure 5B). Relative intensity of immunoblots for 
GPER and CTGF highlighted a significant (p=0.0042) positive correlation between GPER 
and CTGF expression in cancerous tissue but not matched normal controls (Figure 5C). As 
GPER stimulation increases CTGF expression our results indicate greater estrogen 
availability through STS activity in these tumors may lead to increased GPER stimulation 
and CTGF expression (Figure 5D).  
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Discussion 
Here we demonstrate a critical role for pre-receptor local estrogen metabolism and action in 
the proliferation of CRC. For the first time we show estrogen synthesis pathways, via STS, 
HSD17B7 and HSD17B12, are elevated in CRC and estrogens stimulate CRC growth 
through a GPER-mediated mechanism. Of particular importance is STS, a key regulator in 
estrogen activation. When over-expressed in HCT116 cells STS drives greater tumor 
proliferation in in vitro and in vivo models. Finally, we demonstrate E2 acts through GPER 
signaling, most likely via CTGF, in CRC, and that both GPER and CTGF are increased in 
human CRC. Our results suggest that inhibiting GPER or estrogen metabolism may be a 
novel therapeutic option for this malignancy.  
 
Controversy exists on estrogens role in CRC development and progression. The Women's 
Health Initiative (26) has highlighted various questions on how estrogens and progestins 
impact cancer. Epidemiological studies indicate estrogens as protective against CRC 
development. However, how estrogens impact CRC once it has developed is poorly defined. 
It has been suggested that whilst initially protective, estrogens may be mitogenic in CRC (24) 
through changes in local estrogen metabolism and receptor availability. Indeed, estrogens 
promote tumorigenesis in colitis-associated CRC (27), and E2 increases LoVo cell line 
proliferation via up-regulation of fatty acid synthesis (28). However, few studies have 
investigated enzymes involved in estrogen metabolism in CRC, and the ones that have over-
looked key 17HSDs and STS activity. Furthermore, although evidence strongly suggests 
that ER down regulation, and thus the loss of this pro-apoptotic pathway, is an important 
turning-point in CRC development (16), whether GPER expression or stimulation impacts 
CRC has not previously been determined.  
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We show that STS activity is significantly elevated in human CRC and that STS over-
expression stimulates CRC cell proliferation. Previous findings had indicated increased STS 
expression as prognostic for CRC survival (9), however this study did not measure STS 
activity. This is an important distinction. STS is subject to post-translational modifications 
affecting activity and we show here colon STS activity and expression do not correlate. 
Furthermore, analysis of the TCGA COAD database demonstrated no significant changes in 
STS expression in colon cancer compared to normal controls. Although eventual patient 
outcomes have not been determined, we show STS activity does not correlate to Duke’s 
staging or tumor T-stage implying increased STS activity is most likely an early event in 
CRC development, and thus its prognostic significance is questionable (9).  Along with 
increased aromatase expression, elevated STS activity is a hallmark of estrogen-dependent 
cancers (29). STS inhibition is currently in Phase II clinical trials in patients with hormone-
dependent breast cancer, after it had shown promise in pre-clinical studies against E2S-
stimulated breast cancer in vivo as well as in Phase I trials (30). As aromatase expression is 
not detectable in the human colon (9), local desulfation of circulating E1S may act as the 
primary route for estrogen availability in CRC.  
 
Once desulfated, HSD171, HSD177, and HSD1712 reduce E1 to E2, with HSD172 
catalyzing reverse oxidation. Supporting our findings, TCGA COAD analysis and others (23) 
have shown that HSD17B2 expression is down-regulated in CRC, however our data here 
indicates no change in HSD172 protein expression suggesting this pathway may remain 
active. Although HSD171 is the prime reducer of E1 (31) we demonstrate this enzyme is 
absent in CRC. Interestingly, HSD177 and HSD1712 expression are significantly up-
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regulated in CRC compared to matched normal controls, with this effect mimicked at the 
protein level, and our findings are supported by TCGA COAD data analysis. Thus, CRC may 
favor E2 synthesis. Recently, pre-clinical studies show inhibition of HSD17B7 in hormone-
dependent breast cancer blocks E1 to E2 synthesis and thus has therapeutic potential (32). As 
intratumoral E1 and E2 concentrations in CRC tissue pertains to a poor prognosis (9), 
inhibiting these enzymes in CRC may be therapeutically beneficial.  
 
As ER and ER are not present in the CRC cell lines tested, a question arose, how do 
estrogens act in CRC? Limited data on colonic GPER expression exists: GPER stimulation 
may affect colonic motility in mice (33) and its expression may influence abdominal pain 
severity in IBD (34). We demonstrate GPER protein, but only limited mRNA, is expressed in 
human CRC tissue and cell lines. GPER protein expression is elevated in human CRC tissue 
compared to matched normal controls, in contrast to mRNA which is decreased. This may 
imply that GPER protein degradation pathways may be altered in CRC, effectively allowing 
for GPER protein retention.  Stimulation of GPER by E2 or the specific agonist G1 increased 
CRC proliferation in vitro, with this effect blocked by GPER inhibition in in vitro and in vivo 
CRC models. In contrast to our findings, recent research has shown GPER stimulation by G1 
decreases proliferation of various CRC cell lines, including HCT116 (35). However, these 
studies used higher doses of G1 (up to 10 M) compared to our 100 nM dose, and, unlike the 
work presented here, the studies are not performed in stripped-media (i.e. no/low estrogen) 
conditions. Thus, this suggests there may be a biphasic response to G1 and estrogens with 
regards GPER stimulation in CRC, with low doses increasing proliferation and high doses 
inducing apoptosis. This biphasic response is also evident with ER stimulation in breast 
cancer (36).  
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GPER deficiency results in multiple physiological alterations including obesity, 
cardiovascular dysfunction, insulin resistance and glucose intolerance (37), and there is much 
interest in its pro-proliferative effects in breast cancer. In breast cancer patients, GPER 
expression is associated with increased primary tumor size and the prevalence of distant 
metastasis (38). Indeed, GPER-stimulation by tamoxifen is a potential pathway of tamoxifen-
resistant hormone-dependent breast cancer (39) and intriguingly, breast cancer patients 
treated with tamoxifen are more likely to develop CRC (40). Our results strongly implicate 
E2-GPER-mediated action, through CTGF, in CRC proliferation. As the loss of ER defines 
CRC development (16), it will be of interest to further examine GPER action in the context of 
ER expression to determine whether an estrogen receptor “switch” occurs during CRC 
progression.    
 
Furthermore, in CRC cell lines, the expression of CTGF, a known downstream regulator of 
GPER action (21), was elevated by E2 and G1 treatment. A correlation is evident between 
GPER and CTGF expression in human CRC tissue. CTGF is up-regulated in some CRC 
patients (41), although its expression reduces in latter-stage disease (42). Analysis of the 
TCGA COAD dataset also suggests that high CTGF is related to poor patient survival, 
although others have shown high CTGF expression correlates to improved CRC survival 
rates (41). This implies a complicated relationship between E2-stimulation of GPER, 
increased proliferation, CTGF-mediated effects, and patient outcomes. However, in general, 
dysregulation of CTGF expression is linked to poor outcomes in many human cancers (43).  
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In conclusion, we have identified a new estrogen-driven proliferative pathway in CRC. 
Increased STS activity leads to greater estrogen desulfation, thereby increasing HSD17B 
substrate availability for subsequent E2 synthesis, followed by GPER activation and CTGF 
up-regulation. These findings identify STS, 17BHSD7, 17BSHD12, and GPER as potential 
new therapeutic targets for CRC.  
 
Experimental Procedures 
Compounds 
STX64 (Irosustat) was from Sigma-Aldrich Ltd. (Dorset, UK). G1 and G15 were from Torcis 
Bioscience (Abingdon, UK). E1S, E1, E2S, and E2 were from Sigma-Aldrich.  
 
Human tissue and cell culture 
Matched normal and cancerous human colorectal tissue was obtained with local ethics 
committee approval and informed patient consent. CRC samples from patients with genetic 
pre-disposition to CRC, such as familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC) were excluded. Patients currently on HRT were also 
excluded. Patient characteristics and disease stage are outlined in Supplementary Table 1. 
 
HCT116 and HT-29 cells were cultured in McCoy’s 5a modified medium (Life 
Technologies). Caco2 cells were cultured in MEM and JEG-3 cells in DM-F12 (Life 
Technologies). All medium was supplemented with 10% FBS (Sigma-Aldrich) and 2mM L-
glutamine (Sigma-Aldrich). All cell lines were authenticated (March 2014) by short tandem 
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repeat profiling and regularly mycoplasma tested (every 6 months). After 20 passages cells 
were discarded and fresh cells obtained. For all estrogen and GPER antagonist/agonist 
experiments, charcoal stripped FBS was used in phenol-free media. Charcoal-stripping of 
FBS is known to reduce estrogen concentrations to undetectable levels.  
 
Data sets 
Normalized gene expression data generated using the Illuminia RNA-seq platform (accessed 
Jan. 2017) and clinical information was downloaded from cBioPortal (44). Gene expression 
values were transformed as X = log2(X + 1) where X represents the normalized fragments per 
kilobase transcript per million mapped reads (FPKM) values. Transcriptomic and clinical 
information was analyzed for 284 patients with colon cancer. 
 
Generation of STS over-expressing HCT116 cells 
HCT116 cells were transfected using Lipofectamine (Invitrogen, Paisley, UK) with a pCl-neo 
(Promega) construct containing either vector only [vo] or complete coding sequence for the 
human STS [sts] gene. Cells were subsequently grown in 1 mg/mL G418 (Promega).  STS 
activity was routinely measured to determine STS transfection stability.  
 
STS activity assay 
STS activities of human CRC tissue samples and cell lines were measured as previously 
described (45). Briefly, tissue and cell supernatants were incubated with [6,7-
3
H] E1S (4 x 10
5 
dpm, Perkin-Elmer) adjusted to a final concentration of 20 M with unlabeled E1S (Sigma). 
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[4-
14
C] E1 (1 x 10
4
 dpm, Perkin-Elmer) was included to monitor procedural losses. Samples 
were incubated at 37
o
C after which the product, E1, was separated from E1S by partition with 
toluene. 
3
H and 
14
C radioactivity was measured by liquid scintillation spectrometry. Mass of 
E1S hydrolysed was calculated from 
3
H counts detected corrected for procedural losses. 
Results were determined as pmol product formed/h/mg protein. 
qRT-PCR analysis 
From human samples 30mg tissue was homogenised in RLT buffer containing -
mercaptoethanol. cDNA was manufactured with SENSIFast kit (Bioline) using 1g mRNA as 
per the manufacturers’ instructions. From cell lines mRNA was purified using RNeasy kits 
(QIAGEN) as per the manufacturers’ instructions. mRNA samples were reverse transcribed to 
form cDNA using Tetro cDNA Synthesis Kit (Bioline Reagents Ltd.).  
 
Expression of specific mRNAs was determined on a 7500 Real-time PCR system (Applied 
Biosystems) using the QuantiTect Probe RT-PCR kit (Qiagen). Relative expression was 
determined using the 2
-∆∆Ct
 method. Taqman assays are described (Supplementary Table 4) 
 
Immunoblotting 
Blots were probed as outlined in Supplementary Table 5. Secondary antibodies were from 
Santa Cruz, goat anti-mouse (sc-2005) and goat anti-rabbit (sc-2004). Bound antibody was 
detected with horseradish peroxidase-conjugated secondary antibody and 
chemiluminescence. Bands were quantified using Image J software from NCBI 
(http://rsbweb.nih.gov/ij/). Images were converted into binary mode and ratios derived by 
comparing protein of interest bands to -actin.  
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LC-MS/MS 
Estrogens were measured by uHPLC-MS/MS. After addition of internal standard steroids 
(E1S-d4, E2S-d4 (Cambridge Isotopes) and 
13CE2 (Sigma)) samples were extracted using solid 
phase extraction (C18 Isolute SPE columns 500mg, Biotage). Estrogens were quantified 
relative to a calibration series (0.5-500ng/L) via tandem mass spectrometry. A Waters Xevo 
mass spectrometer with an electrospray ionization source was used with an attached Acquity 
liquid chromatography system. Estrogens were eluted from a HSS C18 SB 1.8um, 2.1 x 
30mm column using a methanol/water gradient system with 0.3mM ammonium fluoride 
added to the aqueous phase. The coefficient of variation for all assays was less than 20%. 
 
siRNA Design and Transfection 
The siRNA oligonucleotides and transfection reagents were purchased from Dharmacon, Inc. 
(Lafayette, CO). The predesigned ON-TARGETplus SMARTpool for human GPER and 
human CTGF genes, containing a mixture of four-targeting siRNA oligonucleotides, was 
used for knockdown. An ON-TARGETplus Non-Targeting pool, containing four nonspecific 
siRNA oligonucleotides, was used for control. For siRNA transfection, HCT116 cell were 
cultured overnight and subsequently transfected with control or GPER or CTGF siRNA 
oligonucleotides using DharmaFECT transfection reagent according to the manufacturer’s 
instructions. The medium was changed to sFBS media every 24h, and in certain experiments 
included E2 (100 nM) or G1 (100 nM). Proliferation assays were started 48 h after siRNA 
transfection.  
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In vivo xenograft studies 
Six week old athymic, female CD-1 nude mice (nu−/nu−) were purchased from Charles 
River. All experiments were carried out under conditions that complied with institutional 
guidelines. Five million HCT116 cells were injected s.c. into the right flanks of the animal.  
For STS inhibition studies, when tumors reached 70 to 100mm
3
, mice were randomly divided 
into two treatment groups: oral vehicle (10% ethanol:90% propylene glycol thrice weekly) or 
oral STX64 (20 mg/kg/thrice weekly). For GPER inhibition studies HCT116[sts] bearing 
animals were randomly divided into two treatment groups: i.p. vehicle (0.9% NaCl, 0.1% 
Tween80, 1% EtOH, thrice weekly) and G15 (50 g/kg, i.p. thrice weekly). Mice were 
weighed and tumor measurements taken thrice weekly with the researcher blinded to groups. 
Tumor volumes were calculated using the formula (length × width
2
/2). At the conclusion of 
dosing, animals were terminated and their tumors removed, weighed, and stored at -80
o
C.  
 
Proliferation assays 
Cell proliferation was measured by the CyQuant cell proliferation (Thermo Fisher Scientific) 
and BrdU incorporation assays (Roche Applied Science) as per the manufacturer instructions. 
Prior to experiments, cells were placed into stripped-FBS phenol-red free medium (Thermo 
Scientific) with 5mM L-glutamine for 72h to clear any remaining estrogens in the media. 
Cells were cultured in flat-bottom 96-well plates in either complete or stripped FBS phenol-
free growth media containing estrogens and subsequent assays performed. 
 
Statistics 
For human data the population analyzed was described using summary statistics and 
relationships between STS activity and STS expression investigated by plotting the data and 
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calculating correlation coefficients.  Further analyses used random effects linear regression 
modeling (with outcomes transformed to reduce the impact of outliers where appropriate) to 
allow for normal and cancer samples being patient matched. Models were fitted to investigate 
differences in STS activity, HSD17B7 mRNA expression, HSD17B12 mRNA expression and 
HSD17B2 mRNA expression between normal and cancer cohorts. For the primary analysis 
(investigation of differences in STS activity) models were fitted with and without adjustment 
for patient characteristics (sex, age and BMI) and stage (T and Dukes). For other models, 
adjustment was made for sex and age. Where model outcomes required log transformation 
the estimates obtained are interpreted as approximate percentage differences. 
 
For in vivo experiments involving multiple treatment groups, a one-way ANOVA followed by 
a Tukey multiple comparison test was done to determine statistical significance. Where only 
two groups are compared, a Student's t test was applied. All analysis related to TCGA COAD 
patient survival curves were testified by Kaplan-Meier survival analysis (Log-rank method). 
All statistics were performed on Prism 5.0 software.  
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Figure Legends 
Figure 1: Estradiol synthesis pathways are up-regulated in human CRC. (A) Estrogen 
metabolism pathways demonstrating the importance of STS and HSD17Bs in estrogen 
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synthesis. (B) STS activity is increased in female (n = 29) and male (n = 31) CRC compared 
to matched normal colon tissue. * p < 0.05, ** p < 0.01, *** p < 0.001 using random effects 
linear regression modeling. (C) STS activity does not correlate to STS expression (dCT) in 
CRC or normal colon tissue (n = 62). (D) HSD17B2 (female, n = 19; male, n = 28) 
expression is down-regulated in CRC. * p < 0.05, ** p < 0.01, *** p < 0.001.  (2-tailed paired 
Student’s t test was used). (E) and (F) HSD17B7 (female, n = 21; male, n = 22) and 
HSD17B12 (female, n = 21; male, n = 22) expression is up-regulated in CRC. * p < 0.05, ** 
p < 0.01, *** p < 0.001. (2-tailed paired Student’s t test was used). (G) and (H) representative 
blots and relative intensity (AU) of HSD17B enzymes in normal and matched cancerous 
human colon tissue. HSD17B1 (n = 16) protein expression is not present in human CRC, 
whereas HSD17B7 is expressed, and HSD17B12 expression is increased (n = 16), with little 
change in HSD17B2 expression (n = 16). For relative intensity data, a 2-tailed Student’s t test 
was used. All data represents mean ± s.d.  
 
Figure 2: Estrogens increase proliferation in CRC cell lines. (A) Expression profile of 
HSD17B1, HSD17B2, HSD17B7, and HSD17B12 in HCT116, HT29, Caco-2, and Colo205 
cells. -actin was used as a loading control. 1 representative blot from 3 independent 
experiments. (B) and (C) Estrone (E1) and estradiol (E2) increase proliferation rates in a dose-
dependent manner in HCT116 and HT-29 cells. Caco-2 cells did not respond to E1 or E2 
treatment. (n = 4 independent experiments). (D) and (E) HCT116 cells do not readily 
metabolize E1, E2, and E1S. HT-29 cells metabolize E1 and E2 to an unknown metabolite. 
Caco-2 cells rapidly metabolized E2 to E1. (n = 3 independent experiments). All data 
represents mean ± s.d.  
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Figure 3: Over-expression of STS in HCT116 cells increases estrogen-dependent 
proliferation in vitro and in vivo. (A) HCT116[sts] cells proliferate at a greater rate compared 
to HCT116[vo] cells. This proliferation is significantly inhibited by STX64 (1 mM). ** p < 
0.01, *** p < 0.001. (n= 3 independent experiments, One-way ANOVA followed by a Tukey 
multiple comparison post test). (B) HCT116[sts] cells had increased proliferation when 
stimulated with E2S (100 nM for 72h) compared to HCT116[wt] and HCT116[vo] cells. This 
increased proliferation was blocked by STS inhibition using STX64 (1 mM). *** p < 0.001 
compared to control; ## p < 0.01, ### p < 0.001 compared to E2S treatment; a p < 0.001 
compared to HCT116[vo]. (2-tailed Student’s t test was used, n = 4 independent 
experiments). (C) HCT116[sts] xenografts grow at an increased rate compared to 
HCT116[vo] xenografts. This increased proliferation was inhibited by STX64 (20 
mg/kg/thrice weekly, p.o.). ** p < 0.01, *** p < 0.001. (One-way ANOVA followed by a 
Tukey multiple comparison post test). (D) Five randomly taken tumors imaged after removal. 
(E) Wet tumor weights at 21 days post HCT116 cell inoculation. HCT116[sts] resulted in 
increased tumor burden, which was inhibited by STX64. * p < 0.05, *** p < 0.001. (2-tailed 
Student’s t test was used). (F) STS activity in HCT116[vo] and HCT116[sts] xenografts at 
day 21. HCT116[sts] xenograft maintained elevated STS activity compared to HCT116[vo]. 
STX64 treatment significantly inhibited HCT116[vo] and HCT116[sts] activity. * p < 0.05, 
** p < 0.01, *** p < 0.001. (n = 5 – 14, 2-tailed Student’s t test was used). All data represents 
mean ± s.d.  
 
Figure 4: E2 acts through GPER signaling to increase CRC proliferation. (A) ER and ER 
are not expressed in HCT116 or HT-29, but are present in Caco2 and Colo205 cells. GPER is 
expressed in all cell lines tested. -actin was used as a loading control. 1 representative blot 
from 3 independent experiments. (B) Schematic of the downstream molecular signaling 
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factors stimulated by GPER action as defined in breast cancer. (C) The GPER agonist G1 
increases proliferation rates in a dose dependent manner compared to cells grown only in 
media with SFBS. (2-tailed Student’s t test was used, n = 4 independent experiments) (C) The 
GPER antagonist G15 (1 mM) inhibits the increased proliferation induced by E2 (100 nM for 
72 h) and G1 (100 nM for 72 h) in HCT116 and HT-29 cells. ** p < 0.01, *** p < 0.001 
compared to controls. (2-tailed Student’s t test, n = 4 independent experiments) (D) E2 (100 
nM) and G1 (100 nM) treatment increases CTGF protein expression in HCT116 and HT-29 
cells. -actin was used as a loading control. 1 representative blot from 3 independent 
experiments. (E) siRNA knockdown of GPER and CTGF in HCT116 cells was achieved for 
96h post siRNA treatment. (F) siRNA knockdown of GPER and CTGF inhibits E2 (100 nM) 
and G1 (100 nM) stimulation of HCT116 proliferation. * p < 0.05, *** p < 0.001 compared 
to controls. (Two-way ANOVA followed by a Bonferroni post-test, n = 3). (G) G15 (50 
mg/kg/thrice weekly, i.p.) significantly attenuates HCT116[sts] xenograft tumor growth in 
female nude mice. ** p < 0.01 (Two-way ANOVA, n = 10). (H) Patients with high GPER 
expression (n = 110) had a significantly worse survival outcome compared to mid-low GPER 
expressing (n = 330) CRC tumors, as shown from analysis of the TCGA COAD dataset. 
(Kaplan-Meier survival analysis (Log-rank method). All data represents mean ± s.d.  
Figure 5: CTGF and GPER expression correlate in human CRC. (A) Immunoblotting of 
GPER and CTGF expression in normal (N) and cancerous (C) human colon tissue. -actin 
was used as a loading control. 1 representative blot from 3 independent experiments. (B) 
GPER and CTGF expression are increased in human CRC, as measured by immunoblotting 
relative intensity to -actin * p < 0.05, *** p < 0.001. (2-tailed Student’s t test was used, n = 
17) (C) Correlation between GPER and CTGF relative intensity in normal and cancerous 
human colon tissue. n = 17. (D) Schematic showing proposed novel pathway through which 
estrogens act, via GPER, to augment proliferation in CRC.  
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